By-Health Launches Dietary Supplement Based on Organobalance Ingredient
13 Mar 2017 --- By-Health, the leading Chinese dietary supplement provider, has launched Hericum Erinaceus & Lactobacillus Reuteri, a digestive health product based on Organobalance’s proprietary ingredient Pylopass.
“We are glad to be collaborating with By-Health who will use Pylopass in its product portfolio,” says Professor Christine Lang, microbiologist, founder and General Manager of Organobalance.
“This gives the Chinese people access to an effective and natural way to control the pathogenic stomach bacterium Helicobacter pylori.”
Pylopass is already selling the product in most European, American and Asian markets. In China, 60-80% of the population is infected with H. pylori.
“The ratio is much higher than in Western countries, which is mainly related to the living environment and habits in China,” explains Zhang Xuguang, Director, By-Health Science and Technology Center.
“With increasing awareness of health and the popularity of health checks, people are increasingly concerned about the harm of H. pylori.”
“Our newly launched Hericum Erinaceus & Lactobacillus Reuteri uses Pylopass as a core ingredient, which reflects By-Health brand concept of exploring excellent nutrition globally, to meet the health needs of Chinese consumers.”
“We identified the Pylopass strain with its unique properties out of our large microbial strain collection with several thousand strains,” says Professor Christine Lang.
“Unlike conventional therapies which can harm the human microbiome, Pylopass is highly specific and binds and removes the carcinogenic stomach bacteria, lowering the H. pylori load while keeping the natural gut microbiota balance intact.”
Speaking to NutritionInsight, a spokesperson from Organobalance said: “Our customers use Pylopass for three major product applications: gastric well-being, balancing a healthy microflora, in combination with an antibiotic eradication therapy. Pylopass is currently marketed in most European, American and Asian markets.”
“The possibility to state a health claim depends on the use of Pylopass and the territory. OB provides technical and clinical data to our B2B customers, who then adapt the positioning of their B2C product to local requirements and regulations.”
In addition, resistance against the most commonly used antibiotics for conventional treatment of H. pylori has been increasing strongly during the last 15 years in China from 10-15% in 2000 to 50-60% in 2014, lowering the success rate of antibiotic therapies significantly.
Several clinical studies demonstrated that Pylopass reduces the colonization of H. pylori in the stomach and prevents gastritis and peptic ulcers.
“New studies show that Pylopass can not only reduce the colonization of H. pylori in the stomach, but also improve the symptoms associated with a gastritis and increase the efficacy of the pharmaceutical treatment,” adds Organobalance’s Commercial Director Gilles Jequier.
